Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2007

Galapagos Inks $8.1M Alliance with Cystic Fibrosis Foundation Therapeutics

  • Galapagos is partnering with Cystic Fibrosis Foundation Therapeutics (CFFT) in a deal worth up to $8.1 million. The research will be conducted through Galapagos’ BioFocus DPI service.

    The joint effort will combine BioFocus’ expertise in natural product drug discovery and screening in cells derived from patients. Specifically, the research aims to identify small molecules derived from natural sources that improve the function of CFTR (cystic fibrosis transmembrane conductance regulator). This protein is found defective in people with cystic fibrosis.

    Galapagos will receive $2.4 million over the next two years and up to $5.7 million for research achievements. This collaboration adds to a previously established target discovery agreement between CFFT and Biofocus, signed in 2005.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »